Royal Bank of Canada
CELGZ

Royal Bank of Canada’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Royal Bank of Canada’s Portfolio CELGZ Stock Details CELGZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-3,000
Closed -$9K – 6761
2014
Q4 		$9K Buy
+3,000
New +$10.1K ﹤0.01% 5661
2013
Q3 		– Sell
-3,075
Closed -$23K – 6527
2013
Q2 		$23K Buy
+3,075
New +$22.3K ﹤0.01% 4984

Other funds holding CELGZ

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FA
FCG Advisors Chatham, New Jersey $425M AUM 12.09% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return

Royal Bank of Canada's CELGZ Position: Q1 2015 in Review

Royal Bank of Canada sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q1 2015, closing a stake of 3,000 shares — an estimated $9K sold.

Royal Bank of Canada first reported a position in CELGZ in Q2 2013 and held it in 2 quarters. The position peaked at $23K in Q2 2013. 22 funds tracked by Wall St. Rank hold CELGZ as of Q1 2015.

  • Royal Bank of Canada reported no remaining Celgene Corporation Contingent Value Rights position as of Q1 2015 after selling out during the quarter.
  • Royal Bank of Canada sold 3,000 Celgene Corporation Contingent Value Rights shares in Q1 2015, an estimated $9K.
  • Royal Bank of Canada first reported a position in Celgene Corporation Contingent Value Rights in Q2 2013 and held it in 2 quarters.
  • Royal Bank of Canada's Celgene Corporation Contingent Value Rights position peaked at $23K in Q2 2013.
  • 22 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q1 2015.

Based on Royal Bank of Canada's 13F filing for Q1 2015, filed 15 May 2015.